News
No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...
The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...
Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.
Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.
Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...
Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...
Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results